Next 10 |
home / stock / bgne / bgne articles
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio? Walgreens Boots Alliance, Inc. (NASDAQ:WBA) sh...
Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Br...
These 10 large-cap stocks were the worst performers last week. Are they in your portfolio? National Grid Transco (NYSE:NGG) decreased 1...
With the earnings season in full swing, these large-cap stocks were the best performers in the last week. Are they in your portfolio? Vertiv Holdi...
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...
U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday. Shares of Lululemon Athletica Inc. (NASDAQ: L...
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-exp...
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Shares of The Beauty Health Company ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and tolerability Safety profile was consistent with results o...